Pivotal trial results for upadacitinib (Rinvoq) in psoriatic arthritis were published on January 1, 2021. The study, known as SELECT - PsA 1, compared upadacitinib to placebo and to adalimumab in participants who had an inadequate response to at least one non-biologic disease-modifying anti-rheumatic drug.
Background
Upadacitinib (Rinvoq) was investigated for the treatment of psoriatic arthritis, a chronic inflammatory disease. The trial focused on participants who had previously shown an inadequate response to at least one non-biologic disease-modifying anti-rheumatic drug, indicating a population with ongoing disease activity despite conventional therapies.
Trial design
The SELECT - PsA 1 study was a pivotal trial designed to evaluate upadacitinib (ABT-494) in participants diagnosed with psoriatic arthritis. The study specifically enrolled individuals who had demonstrated an inadequate response to at least one non-biologic disease-modifying anti-rheumatic drug. The trial's design included multiple arms, comparing upadacitinib against both a placebo arm and an active comparator arm using adalimumab. This comparative approach aimed to assess the efficacy and safety profile of upadacitinib relative to existing treatment standards and non-treatment.
What this means
The publication of these pivotal trial results for upadacitinib in psoriatic arthritis provides important new data for the medical community. While specific efficacy or safety outcomes are not detailed in the provided information, the completion and publication of a study comparing a new therapy against both placebo and an established biologic like adalimumab is significant. This allows clinicians and researchers to delve into the full published findings to understand upadacitinib's potential role in managing psoriatic arthritis, particularly for patients who have not responded adequately to prior non-biologic treatments. Patient advocates can also review the data to inform discussions about treatment options.
Source
The information regarding the publication of these trial results was sourced from PubMed. The article, titled "Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis," was published on January 1, 2021, and is accessible via pubmed.ncbi.nlm.nih.gov. This publication details the SELECT - PsA 1 study, which compared upadacitinib to placebo and adalimumab.